TABLE 1.
SARS‐CoV‐2 screening methods (Q11–Q12, Q24)
| n = 321 responses | % | |
|---|---|---|
| Q11. Did/Do you perform (or ask your patients) to bring a negative SARS‐CoV‐2 test for patients requiring face‐to‐face visits before consultation? | ||
| Yes, to all | 22 | 6.85 |
| No, only a pre‐visit triage questionnaire was/is performed | 238 | 74.15 |
| Yes, but only in patients who needed spirometry or other high‐risk procedures (spread by aerosolization) | 61 | 19.00 |
| n = 116 responses | % | |
|---|---|---|
| Q12. If the answer was “yes,” how much time before the visit was the SARS‐CoV‐2 testing performed? | ||
| 24 h | 29 | 25.00 |
| 48 h | 43 | 37.07 |
| 72 h | 30 | 25.86 |
| >72 h | 14 | 12.07 |
| n = 300 responses | % | |
|---|---|---|
| Q24. In your opinion, which of the following allergy practices increase the risk of COVID‐19 infection spread by aerosolization? You may choose more than one option below | ||
| Spirometry test | 276 | 92.00 |
| Peak flow meter device | 198 | 66.00 |
| Exercise test | 203 | 67.67 |
| Food or drug challenge tests | 23 | 7.67 |
| Skin prick tests | 12 | 4.00 |
| Oral immunotherapy | 9 | 3.00 |
| Allergen immunotherapy for inhalant allergy | 7 | 2.33 |
| Insect venom immunotherapy | 4 | 1.33 |
| Don’t know | 11 | 3.67 |
Abbreviations: COVID‐19, Coronavirus disease 2019; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2.